About Pharmaids Pharmaceuticals Limited
Data last updated:
Pharmaids Pharmaceuticals Limited is a public limited company based in Bangalore, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 March 1989 and has been in existence for over 37 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN L52520KA1989PLC173979. Its GSTIN is 29AABCP4657N1ZS (Karnataka). The company holds 4 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 524572.
The company has an authorised share capital of ₹101 Cr and a paid-up capital of ₹35.27 Cr. It was formerly known as Pharmaids Pharmacuticals Private Limited. It is led by directors including Venu Madhava Kaparthy (Whole-Time Director) and Mini Manikantan (Whole-Time Director).
Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Bangalore, Karnataka.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹27.88 Cr, a growth of 43.3% compared to the previous year. For the same year it recorded a net loss of ₹14.19 Cr (net margin -50.9%) and EBITDA of -₹13.8 Cr (EBITDA margin -49.5%). The net worth stands at ₹47.66 Cr (down 19.7% YoY). Total assets are valued at ₹72.96 Cr (down 24.8% YoY).
The company has about 21 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Pharmaids. As per MCA filings, the company has open charges of ₹10.49 Cr and satisfied charges of ₹1.85 Cr on record. Court records list 21 cases involving the company, including 14 filed by the company and 7 filed against it; 4 cases are pending. The company has 63 deals on record (62 market trades, 1 funding round); the latest was in January 2024.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website pharmaids.com.
Company details
CIN history
Pharmaids Pharmaceuticals has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L52520KA1989PLC173979, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L52520KA1989PLC173979 | Current |
| U52520AP1989PLC009679 | Previous |
| L52520AP1989PLC009679 | Previous |
| L52520TG1989PLC009679 | Previous |
Contact details
Pharmaids Pharmaceuticals Limited's registered office is in Bangalore, Karnataka. Its website is pharmaids.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressUnit 201 2nd Floor Brigade Rubix 20/14, Hmt Factory Main Road Peenya Plantation, Bangalore, Karnataka, India – 560013
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Pharmaids Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Pharmaids Pharmaceuticals operates one associated brand: Pharmaids. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaids is recognized as a provider of custom research and manufacturing services for pharmaceutical and related industries. | pharmaids.com |
Financials of Pharmaids Pharmaceuticals Limited
FY 2025-26 filings availablePharmaids Pharmaceuticals Limited reported revenue of ₹27.88 Cr (up 43.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 27.88 | 19.45 | 15.11 | 0.00 | 3.94 |
| Revenue growth | +43.3% | +28.7% | - | -100.0% | - |
| EBITDA | (13.80) | (12.89) | (13.20) | (9.89) | 0.14 |
| EBITDA margin | -49.5% | -66.3% | -87.4% | - | +3.6% |
| Profit before tax | (16.31) | (17.28) | (15.62) | (9.91) | 0.15 |
| Net profit | (14.19) | (10.67) | (7.11) | (7.56) | 0.15 |
| Net profit margin | -50.9% | -54.9% | -47.1% | - | +3.8% |
| EPS (₹) | (3.32) | (3.06) | (2.26) | (3.52) | 0.14 |
| Balance sheet | |||||
| Total assets | 72.96 | 96.99 | 82.24 | 22.46 | 8.67 |
| Net worth | 47.66 | 59.32 | 72.05 | 22.46 | 8.67 |
| Total debt | 23.39 | 38.98 | 8.53 | 0.00 | 0.00 |
| Cash & bank | 0.13 | 0.82 | 4.80 | 12.75 | 0.41 |
| Net working capital | (3.32) | (1.88) | 4.43 | 12.08 | 0.23 |
| Cash flow | |||||
| Cash from operations | (4.06) | (15.11) | (10.62) | (4.02) | (0.26) |
| Cash from investing | 23.34 | (12.22) | (74.99) | (4.94) | 0.47 |
| Cash from financing | (19.97) | 23.36 | 77.66 | 21.31 | 0.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.12 | 7.18 | 5.43 | 8.61 | 6.66 | 4.77 | 4.71 | 5.24 |
| Revenue growth (YoY) | -38.1% | +50.5% | +15.3% | +64.3% | +40.8% | - | - | - |
| Other income | 4.25 | 0.10 | 0.08 | 3.03 | 0.04 | 0.13 | 0.01 | 0.08 |
| EBITDA | (0.75) | (0.43) | (2.90) | (5.32) | (5.38) | (3.91) | (2.90) | (2.41) |
| EBITDA margin | -18.2% | -6.0% | -53.4% | -61.8% | -80.8% | -82.0% | -61.6% | -46.0% |
| Depreciation | 0.49 | 0.48 | 0.48 | 0.47 | 0.61 | 0.62 | 0.64 | 0.61 |
| Interest | 0.60 | 0.65 | 0.72 | 0.93 | 1.20 | 1.01 | 0.48 | 0.33 |
| Profit before tax | 2.41 | (1.46) | (4.02) | (3.69) | (7.15) | (5.41) | (4.01) | (3.27) |
| Tax | 0.54 | (0.37) | (1.38) | (1.13) | (1.86) | (0.60) | (1.00) | (1.00) |
| Net profit | 1.87 | (1.09) | (2.64) | (2.56) | (5.29) | (4.81) | (3.01) | (2.27) |
| EPS (₹) | 0.63 | (0.51) | (0.70) | (0.70) | (1.39) | (1.11) | (0.55) | (0.73) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 10.60 | 2.34 | 0.03 | 0.00 | 3.94 | 8.55 | 0.00 |
| Revenue growth | +353.0% | +7700.0% | - | -100.0% | -53.9% | - | - |
| EBITDA | (14.26) | (7.26) | (6.36) | (9.90) | 0.14 | 0.11 | (0.33) |
| EBITDA margin | -134.5% | -310.3% | - | - | +3.6% | +1.3% | - |
| Profit before tax | (13.97) | (8.59) | (6.07) | (9.92) | 0.15 | 0.10 | (0.37) |
| Net profit | (13.56) | (7.28) | (4.93) | (7.57) | 0.15 | 0.10 | 0.04 |
| Net profit margin | -127.9% | -311.1% | - | - | +3.8% | +1.2% | - |
| EPS (₹) | (2.96) | (2.06) | (1.40) | (3.52) | 0.14 | 0.09 | 0.03 |
| Balance sheet | |||||||
| Total assets | 74.02 | 99.64 | 84.04 | 22.43 | 8.67 | 8.53 | 8.43 |
| Net worth | 53.38 | 63.79 | 71.06 | 22.42 | 8.67 | 8.53 | 8.43 |
| Total debt | 20.63 | 35.74 | 12.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.11 | 0.47 | 2.46 | 12.75 | 0.41 | 0.20 | 0.02 |
| Net working capital | (4.12) | (2.39) | 3.81 | 12.87 | 0.23 | 0.27 | 0.35 |
| Cash flow | |||||||
| Cash from operations | (3.53) | (7.72) | (3.44) | (4.02) | (0.26) | 0.41 | (0.75) |
| Cash from investing | 24.53 | (18.90) | (72.51) | (4.95) | 0.47 | (0.23) | 0.66 |
| Cash from financing | (21.36) | 24.64 | 65.66 | 21.31 | 0.00 | 0.00 | 0.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.69 | 0.83 | 5.97 | 1.12 | 0.13 | 1.21 | 0.83 |
| Revenue growth (YoY) | -100.0% | +1969.2% | -31.4% | +619.3% | +558.8% | - | - | - |
| Other income | 4.25 | 0.06 | 0.06 | 3.32 | 0.35 | 1.01 | 0.00 | 0.01 |
| Total expenses | 0.87 | 3.79 | 4.51 | 10.54 | 5.99 | 2.81 | 2.94 | 1.96 |
| EBITDA | (0.87) | (1.10) | (3.68) | (4.57) | (4.87) | (2.68) | (1.73) | (1.13) |
| EBITDA margin | - | -40.9% | -443.4% | -76.5% | -434.8% | -2061.5% | -143.0% | -136.1% |
| Depreciation | 0.06 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 |
| Interest | 0.57 | 0.60 | 0.57 | 1.02 | 1.11 | 2.05 | 0.07 | 0.01 |
| Profit before tax | 2.75 | (1.69) | (4.24) | (2.33) | (5.68) | (3.77) | (1.85) | (1.18) |
| Tax | 0.61 | (0.38) | (1.13) | (0.68) | (1.33) | (0.72) | (0.25) | (0.18) |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.12 | 7.18 | 5.43 | 8.61 | 6.66 | 4.77 | 4.71 | 5.24 |
| Revenue growth (YoY) | -38.1% | +50.5% | +15.3% | +64.3% | +40.8% | - | - | - |
| Other income | 4.25 | 0.10 | 0.08 | 3.03 | 0.04 | 0.13 | 0.01 | 0.08 |
| EBITDA | (0.75) | (0.43) | (2.90) | (5.32) | (5.38) | (3.91) | (2.90) | (2.41) |
| EBITDA margin | -18.2% | -6.0% | -53.4% | -61.8% | -80.8% | -82.0% | -61.6% | -46.0% |
| Depreciation | 0.49 | 0.48 | 0.48 | 0.47 | 0.61 | 0.62 | 0.64 | 0.61 |
| Interest | 0.60 | 0.65 | 0.72 | 0.93 | 1.20 | 1.01 | 0.48 | 0.33 |
| Profit before tax | 2.41 | (1.46) | (4.02) | (3.69) | (7.15) | (5.41) | (4.01) | (3.27) |
| Tax | 0.54 | (0.37) | (1.38) | (1.13) | (1.86) | (0.60) | (1.00) | (1.00) |
| Net profit | 1.87 | (1.09) | (2.64) | (2.56) | (5.29) | (4.81) | (3.01) | (2.27) |
| EPS (₹) | 0.63 | (0.51) | (0.70) | (0.70) | (1.39) | (1.11) | (0.55) | (0.73) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 27.88 | 19.45 | 15.11 | 0.00 | 3.94 |
| Revenue growth | +43.3% | +28.7% | - | -100.0% | - |
| Other income | 3.04 | 0.15 | 0.88 | 0.00 | 0.02 |
| Total expenses | 41.68 | 32.34 | 28.31 | 9.89 | 3.80 |
| Employee cost | 13.38 | 13.16 | 9.20 | 1.13 | 0.04 |
| EBITDA | (13.80) | (12.89) | (13.20) | (9.89) | 0.14 |
| EBITDA margin | -49.5% | -66.3% | -87.4% | - | +3.6% |
| Depreciation | 2.03 | 2.44 | 1.72 | 0.02 | 0.01 |
| Interest | 3.52 | 2.10 | 1.58 | 0.00 | 0.00 |
| Profit before tax | (16.31) | (17.28) | (15.62) | (9.91) | 0.15 |
| Tax | (4.73) | (3.78) | (3.78) | (2.35) | 0.00 |
| Net profit | (14.19) | (10.67) | (7.11) | (7.56) | 0.15 |
| Net profit margin | -50.9% | -54.9% | -47.1% | - | +3.8% |
| EPS (₹) | (3.32) | (3.06) | (2.26) | (3.52) | 0.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 35.27 | 35.27 | 35.27 | 21.44 | 10.27 |
| Reserves & surplus | 12.39 | 24.05 | 36.78 | 0.67 | (1.60) |
| Shareholders' funds (net worth) | 47.66 | 59.32 | 72.05 | 22.46 | 8.67 |
| Minority interest | (0.05) | (4.28) | (1.55) | 0.00 | 0.00 |
| Secured loans | 4.98 | 3.34 | 0.61 | 0.00 | 0.00 |
| Unsecured loans | 18.41 | 35.64 | 7.92 | 0.00 | 0.00 |
| Total debt | 23.39 | 38.98 | 8.53 | 0.00 | 0.00 |
| Total liabilities | 72.96 | 96.99 | 82.24 | 22.46 | 8.67 |
| Assets | |||||
| Gross block | 58.96 | 81.24 | 65.20 | 0.12 | 0.51 |
| Net block | 53.94 | 76.61 | 63.42 | 0.10 | 0.03 |
| Capital work in progress | 6.10 | 4.53 | 7.00 | 2.00 | 0.45 |
| Investments | 0.00 | 0.00 | 0.00 | 3.31 | 0.00 |
| Inventories | 0.41 | 12.18 | 3.59 | 0.00 | 0.89 |
| Sundry debtors | 3.43 | 3.13 | 2.68 | 1.39 | 1.34 |
| Cash & bank balances | 0.13 | 0.82 | 4.80 | 12.75 | 0.41 |
| Loans & advances | 7.01 | 4.85 | 2.46 | 0.07 | 0.03 |
| Total current assets | 10.98 | 20.98 | 13.53 | 14.21 | 2.67 |
| Total current liabilities | 14.30 | 22.86 | 9.10 | 2.13 | 2.44 |
| Net working capital | (3.32) | (1.88) | 4.43 | 12.08 | 0.23 |
| Total assets | 72.96 | 96.99 | 82.24 | 22.46 | 8.67 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 0.82 | 4.80 | 12.75 | 0.41 | 0.20 |
| Net cash from operating activities | (4.06) | (15.11) | (10.62) | (4.02) | (0.26) |
| Net cash from investing activities | 23.34 | (12.22) | (74.99) | (4.94) | 0.47 |
| Net cash from financing activities | (19.97) | 23.36 | 77.66 | 21.31 | 0.00 |
| Net change in cash | (0.69) | (3.98) | (7.95) | 12.35 | 0.21 |
| Closing cash | 0.13 | 0.82 | 4.80 | 12.75 | 0.41 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +43.3% | +28.7% | - | -100.0% | - |
| EBITDA growth | -7.1% | +2.4% | -33.5% | -7164.3% | - |
| PBT growth | +5.6% | -10.6% | -57.6% | - | +9997.0% |
| Net income growth | -33.0% | -50.1% | +6.0% | -5140.0% | - |
| Revenue CAGR (3Y) | - | +70.3% | - | - | - |
| EBITDA CAGR (3Y) | +11.7% | - | - | - | - |
| Profitability & leverage | |||||
| Net income margin | -41.5% | -69.4% | -78.4% | - | +3.8% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | +1.4% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | +1.4% |
| Debt / equity | 0.58 | 0.36 | 0.09 | 0.00 | 0.00 |
| Long-term debt / equity | 0.44 | 0.30 | 0.06 | 0.00 | 0.00 |
| Interest cover | -22.24 | -13.70 | -10.59 | 0.00 | 0.00 |
| Efficiency & per share | |||||
| Fixed asset turnover | 0.40 | 0.27 | 0.46 | 0.00 | 7.73 |
| Inventory turnover | 4.43 | 2.47 | 8.42 | 0.00 | 4.43 |
| Debtors turnover | 8.50 | 6.70 | 7.43 | 0.00 | 2.94 |
| EPS (₹) | (3.32) | (3.06) | (2.26) | (3.52) | 0.14 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 13.51 | 16.82 | 20.43 | 10.31 | 8.44 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.69 | 0.83 | 5.97 | 1.12 | 0.13 | 1.21 | 0.83 |
| Revenue growth (YoY) | -100.0% | +1969.2% | -31.4% | +619.3% | +558.8% | - | - | - |
| Other income | 4.25 | 0.06 | 0.06 | 3.32 | 0.35 | 1.01 | 0.00 | 0.01 |
| Total expenses | 0.87 | 3.79 | 4.51 | 10.54 | 5.99 | 2.81 | 2.94 | 1.96 |
| EBITDA | (0.87) | (1.10) | (3.68) | (4.57) | (4.87) | (2.68) | (1.73) | (1.13) |
| EBITDA margin | - | -40.9% | -443.4% | -76.5% | -434.8% | -2061.5% | -143.0% | -136.1% |
| Depreciation | 0.06 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 |
| Interest | 0.57 | 0.60 | 0.57 | 1.02 | 1.11 | 2.05 | 0.07 | 0.01 |
| Profit before tax | 2.75 | (1.69) | (4.24) | (2.33) | (5.68) | (3.77) | (1.85) | (1.18) |
| Tax | 0.61 | (0.38) | (1.13) | (0.68) | (1.33) | (0.72) | (0.25) | (0.18) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 10.60 | 2.34 | 0.03 | 0.00 | 3.94 | 8.55 | 0.00 |
| Revenue growth | +353.0% | +7700.0% | - | -100.0% | -53.9% | - | - |
| Other income | 3.81 | 1.02 | 0.80 | 0.00 | 0.02 | 0.03 | 0.00 |
| Total expenses | 24.86 | 9.60 | 6.39 | 9.90 | 3.80 | 8.44 | 0.33 |
| Employee cost | 5.40 | 3.42 | 1.99 | 1.13 | 0.04 | 0.04 | 0.02 |
| EBITDA | (14.26) | (7.26) | (6.36) | (9.90) | 0.14 | 0.11 | (0.33) |
| EBITDA margin | -134.5% | -310.3% | - | - | +3.6% | +1.3% | - |
| Depreciation | 0.21 | 0.20 | 0.18 | 0.02 | 0.01 | 0.04 | 0.04 |
| Interest | 3.31 | 2.15 | 0.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (13.97) | (8.59) | (6.07) | (9.92) | 0.15 | 0.10 | (0.37) |
| Tax | (3.52) | (1.31) | (1.14) | (2.35) | 0.00 | 0.00 | (0.41) |
| Net profit | (13.56) | (7.28) | (4.93) | (7.57) | 0.15 | 0.10 | 0.04 |
| Net profit margin | -127.9% | -311.1% | - | - | +3.8% | +1.2% | - |
| EPS (₹) | (2.96) | (2.06) | (1.40) | (3.52) | 0.14 | 0.09 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 35.27 | 35.27 | 35.27 | 21.44 | 10.27 | 10.27 | 10.27 |
| Reserves & surplus | 18.11 | 28.52 | 35.79 | 0.98 | (1.60) | (1.74) | (1.84) |
| Shareholders' funds (net worth) | 53.38 | 63.79 | 71.06 | 22.42 | 8.67 | 8.53 | 8.43 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 20.63 | 35.74 | 12.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 20.63 | 35.74 | 12.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 74.02 | 99.64 | 84.04 | 22.43 | 8.67 | 8.53 | 8.43 |
| Assets | |||||||
| Gross block | 8.64 | 24.57 | 16.75 | 0.12 | 0.51 | 0.51 | 0.51 |
| Net block | 8.05 | 24.18 | 16.56 | 0.10 | 0.03 | 0.04 | 0.09 |
| Capital work in progress | 5.47 | 3.51 | 2.30 | 2.00 | 0.45 | 0.45 | 0.45 |
| Investments | 52.54 | 52.61 | 52.60 | 3.27 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 9.77 | 0.23 | 0.00 | 0.89 | 0.37 | 0.00 |
| Sundry debtors | 1.38 | 0.16 | 0.00 | 2.05 | 1.34 | 0.28 | 0.00 |
| Cash & bank balances | 0.11 | 0.47 | 2.46 | 12.75 | 0.41 | 0.20 | 0.02 |
| Loans & advances | 4.33 | 2.29 | 2.07 | 0.20 | 0.03 | 0.01 | 0.36 |
| Total current assets | 5.82 | 12.69 | 4.76 | 15.00 | 2.67 | 0.86 | 0.38 |
| Total current liabilities | 9.94 | 15.08 | 0.95 | 2.13 | 2.44 | 0.59 | 0.03 |
| Net working capital | (4.12) | (2.39) | 3.81 | 12.87 | 0.23 | 0.27 | 0.35 |
| Total assets | 74.02 | 99.64 | 84.04 | 22.43 | 8.67 | 8.53 | 8.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.47 | 2.46 | 12.75 | 0.41 | 0.20 | 0.02 | 0.11 |
| Net cash from operating activities | (3.53) | (7.72) | (3.44) | (4.02) | (0.26) | 0.41 | (0.75) |
| Net cash from investing activities | 24.53 | (18.90) | (72.51) | (4.95) | 0.47 | (0.23) | 0.66 |
| Net cash from financing activities | (21.36) | 24.64 | 65.66 | 21.31 | 0.00 | 0.00 | 0.00 |
| Net change in cash | (0.36) | (1.99) | (10.29) | 12.35 | 0.21 | 0.18 | (0.09) |
| Closing cash | 0.11 | 0.47 | 2.46 | 12.75 | 0.41 | 0.20 | 0.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +353.0% | +7700.0% | - | -100.0% | -53.9% | - | - |
| EBITDA growth | -96.4% | -14.2% | +35.8% | -7171.4% | +27.3% | +133.3% | - |
| PBT growth | -62.6% | -41.5% | +38.8% | - | +50.0% | +9998.0% | -146.7% |
| Net income growth | -86.3% | -47.7% | +34.9% | -5146.7% | +50.0% | +150.0% | - |
| Revenue CAGR (3Y) | - | -15.9% | -84.8% | - | +91.6% | +166.8% | -100.0% |
| EBITDA CAGR (3Y) | +12.9% | - | - | +210.7% | - | - | -1.9% |
| Profitability & leverage | |||||||
| Net income margin | -98.6% | -311.1% | - | - | +3.8% | +1.2% | - |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | +1.4% | +0.8% | -3.9% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | +1.4% | +0.8% | +0.3% |
| Debt / equity | 0.48 | 0.36 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.43 | 0.36 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -22.87 | -28.82 | -5.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.64 | 0.11 | 0.00 | 0.00 | 7.73 | 16.76 | 0.00 |
| Inventory turnover | 2.17 | 0.47 | 0.26 | 0.00 | 6.25 | 46.22 | 0.00 |
| Debtors turnover | 13.77 | 29.25 | 0.03 | 0.00 | 4.86 | 61.07 | 0.00 |
| EPS (₹) | (2.96) | (2.06) | (1.40) | (3.52) | 0.14 | 0.09 | 0.03 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 15.14 | 18.09 | 20.15 | 10.46 | 8.44 | 8.30 | 8.21 |
To see the full year-wise statements and ratios of Pharmaids Pharmaceuticals Limited, buy the company report.
Board of directors and KMP of Pharmaids Pharmaceuticals Limited
Pharmaids Pharmaceuticals Limited currently reports 7 directors and 2 key managerial personnel. 20 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pattamadai Natarajasarma Vijay Also directs: Jindal Drilling and Industries Limited, Nayara Energy Limited, Rainbow Digital Services Pvt Ltd and 1 more | Director | 31 Oct 2022 | 3 Years 11 Months | Current |
| Balagangadhara Bidanagere Channathimmaiah Also directs: Adita Bio Sys Private Limited, Siri Labvivo Diet Private Limited | Cfo | 13 Oct 2022 | 4 Years 0 Months | Current |
| Venu Madhava Kaparthy Also directs: Four Seasons Energy Ventures Private Limited | Whole-Time Director | 21 May 2022 | 4 Years 5 Months | Current |
| Mini Manikantan | Whole-Time Director | 09 Jul 2022 | 4 Years 3 Months | Current |
| Nagesh Methuku Also directs: Adita Bio Sys Private Limited | Director | 29 Nov 2022 | 3 Years 10 Months | Current |
| Yogananda Moolemath | Director | 01 Jan 2026 | 0 Years 9 Months | Current |
Auditor
Pharmaids Pharmaceuticals Limited is audited by PPKG & CO for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PPKG & CO | FY 2022 | 009655S |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 33.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 67.00%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 33.00% | 33.00% | 33.00% | 5.10% |
| Public | 67.00% | 67.00% | 67.00% | 94.90% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Sep 2025 | 101179083 | Axis Bank Limited | ₹6.75 Cr | Open | |
| 25 Sep 2025 | 101187894 | State Bank of India | ₹3.74 Cr | Open | |
| 15 Sep 2015 | 100025354 | Others | ₹1 Cr | Satisfied | |
| 10 Sep 1996 | 90117142 | Central Bank of India | ₹5 Lakh | Satisfied | |
| 31 Jul 1995 | 90115182 | Central Bank of India | ₹30 Lakh | Satisfied |
To see the full charge records of Pharmaids Pharmaceuticals Limited, buy the company report.
Total charge records: 7 View all charges
Deals & funding
Pharmaids Pharmaceuticals Limited has 63 deals on record (62 market trades, 1 funding round); the latest was in January 2024.
Deals on record (5 of 63)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2024 | Funding round | Undisclosed | Investors: Tumkur Trade Center Private Limited , an individual |
| Dec 2022 | Market trade | ₹1.01 Cr | Buyer: Topgain Finance Private Limited , Epitome Trading And Investments |
| Dec 2022 | Market trade | ₹64.6 Lakh | Buyer: Epitome Trading And Investments, Topgain Finance Private Limited Seller: Multiplier Share and Stock Advisors Private Limited |
| Dec 2022 | Market trade | ₹1.13 Cr | Buyer: Epitome Trading And Investments, Multiplier Share and Stock Advisors Private Limited , BP Equities Private Limited Seller: BP Equities Private Limited |
| Jun 2021 | Market trade | ₹44.2 Lakh | Buyer: Alpha Leon Enterprises LLP |
To see the full deal history of Pharmaids Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Pharmaids Pharmaceuticals Limited has 21 court cases on record: 14 filed by Pharmaids Pharmaceuticals, 7 filed against it. 4 cases are pending and 17 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 15 | 3 | 2 |
| District courts | 6 | 4 | 2 |
Cases on record (5 of 21)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court | Court case ((T)OP(TM)) | Filed against the company by United Biotech Private Limited | Disposed |
| District court, BENGALURU, Karnataka | Civil suit | Filed against the company by Micro Labs Ltd | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed by the company against Anugraha Chemicals | Pending |
| District court, Visakapatnam, Andhra Pradesh | Court case (CRLA.MU) | Filed by the company against State Rep.By P.P and Another Visakhapatnam and 1 other | Pending |
| High Court, TELANGANA | Appeal | Filed against the company by an individual | Pending |
To see the full case history of Pharmaids Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Pharmaids Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Pharmaids Pharmaceuticals has 4 GST registrations: 1 active and 3 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AABCP4657N1ZS | Karnataka | Active | 18 Nov 2022 |
To see the full GST registrations and return filing status of Pharmaids Pharmaceuticals Limited, buy the company report.
Recent activity
Pharmaids Pharmaceuticals Limited has 41 board changes on record since 2002: 25 appointments and 16 cessations. The latest: Mopperthy Sudheer ceased to be Director on 06 Jan 2026.
49 earlier events are in the company report.
News
Frequently asked questions
Pharmaids Pharmaceuticals is an active public limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 March 1989 (37+ years old) and is registered under CIN L52520KA1989PLC173979. Listed on BSE: 524572.
Pharmaids Pharmaceuticals reported revenue of ₹27.88 Cr for FY 2025-26 (up 43.3% YoY) based on consolidated financials.
Pharmaids Pharmaceuticals has 9 current directors and KMP:
- Venu Madhava Kaparthy - Whole-Time Director
- Mini Manikantan - Whole-Time Director
- Pattamadai Natarajasarma Vijay - Director
- Nagesh Methuku - Director
- Yogananda Moolemath - Director
- Shankarappa Nagaraja Vinaya Babu - Director
- Shreedhara Shetty - Director
- Balagangadhara Bidanagere Channathimmaiah - Cfo
- Prasanna Subramanya Bhat - Company Secretary
The latest financial statements of Pharmaids Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 23 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Pharmaids Pharmaceuticals is 29AABCP4657N1ZS, registered in Karnataka. The company has 4 GST registrations in all, of which 1 is active and 3 are cancelled or inactive.
The CIN (Corporate Identification Number) of Pharmaids Pharmaceuticals is L52520KA1989PLC173979. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Pharmaids Pharmaceuticals is a listed company as per MCA records. Its shares are listed on BSE (code: 524572).
Pharmaids Pharmaceuticals has 21 court cases on record: 14 filed by the company and 7 filed against it. 4 are pending. Most are in the high courts.
Pharmaids Pharmaceuticals was incorporated on 01 March 1989, making it 37+ years old. It is registered with the Registrar of Companies, Bangalore.
Pharmaids Pharmaceuticals has 63 deals on record (62 market trades, 1 funding round); the latest was in January 2024.